Home | By sponsor

CENTER OF MOLECULAR IMMUNOLOGY

Trials shown by sponsor

Public titlesort icon Date of Registration State
14F7 in chronic B-cell lymphoproliferative syndrome 07/03/2018 Registered
14F7 MAb marked with Tc99 Phase II in breast tumors. 2010-12-29 Registered
188Re-marked Ior C5 MAb in persistent or relapsing ovary epithelial cancer, phase I. 2010-12-27 Registered
1B8 vs MabThera® in patients with Diffuse large B-cell lymphoma 01/09/2016 Registered
1E10 anti-idiotype vaccine, metastatic breast cancer, phase II 2010-12-27 Registered
1E10 anti-idiotype vaccine, metastatic colon, phase II. 2010-12-03 Registered
99mtc-marked 14f7 MAb in colon/rectum tumor, Phase II 2010-12-17 Registered
99mTc-marked 14F7 MaB in metastatic breast, phase II 2008-12-27 Registered
Advanced breast cancer treatment with hR3 monoclonal antibody combined with doxorubicin and cyclophosphamide, phase I. 2010-12-17 Registered
Anti-idiotype 1E10 vaccine in advanced non- small cell lung (NSCLC) patients 2010-12-28 Registered
Anti-idiotype 1E10 vaccine in the treatment of patients with small cell lung (SCLC) patients 2010-12-28 Registered
Biomodulina T- CIMAvax-EGF-Advanced Non-Small Cell Lung Cancer-Adults 18/03/2021 Registered
CIMAbior® in CD20-positive B-cell Non-Hodgkin Lymphoma 05/09/2017 Registered
CIMAVax EGF in Lung Cancer in PHC. Phase IV 05/08/2014 Registered
CIMAvax-EGF in Bladder cancer 11/08/2020 Registered
CIMAvax-EGF in different maintenance schemes 12/05/2021 Registered
CIMAvax-EGF in patients at high risk of lung cancer 22/10/2020 Registered
CIMAvax-EGF vaccine Predictor Phase IV 14/12/2015 Registered
CIMAvax-EGF-Platelets-Adults- Lung Cancer 03/08/2018 Registered
CIMAvax-EGF/Lung cancer/Biomarkers/Prospective CT 20/10/2021 Registered